The 11 most recent market catalysts affecting $SNN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 65
Smith+Nephew Receives 510(k) Clearance From FDA And Completes First Surgical Cases With LANDMARK Total Knee System
Smith+Nephew's announcement of FDA 510(k) clearance and the completion of initial surgical cases for its LANDMARK Total Knee System is a positive development. This signifies a new …
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Initiates Coverage On Smith & Nephew with Neutral Rating
BTIG analyst Ryan Zimmerman initiated coverage on Smith & Nephew (SNN) with a Neutral rating. This event is significant because new analyst coverage, especially from a prominent fi…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
Smith & Nephew shares are trading lower after the company reported H1 financial results and cut its FY26 sales guidance below estimates.
The headline signals a significant negative corporate catalyst for Smith & Nephew. Lowered FY26 sales guidance, especially below estimates, suggests a fundamental re-evaluation of …
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
CORRECTION: Smith & Nephew Lowers FY2026 Sales Guidance from $6.534B to $6.411B vs $6.565B Est
Smith & Nephew (SNN) announced a significant reduction in its FY2026 sales guidance, lowering it from $6.534 billion to $6.411 billion. This new forecast is also below the consensu…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Smith+Nephew Expects 2026 Revenue Growth of Around 4% Vs. Previously of Approx 6%
Smith+Nephew's downgrade of its 2026 revenue growth expectations from approximately 6% to around 4% is a significant negative catalyst. This 200 basis point reduction implies a mat…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Smith & Nephew H1 Adj. EPS $0.48 Up From $0.43 YoY, Sales $3.097B Vs. $2.961B YoY
This headline is a significant corporate catalyst for Smith & Nephew, demonstrating robust financial health with increased adjusted EPS and sales. The positive year-over-year growt…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 75
Smith+Nephew shares are trading lower amid possible sympathy with Stryker after that company reported Q2 financial results and had BTIG and Piper Sandler lower their respective price targets on the stock.
This headline indicates a significant corporate catalyst impacting the medical device sector. Stryker's Q2 results, coupled with analyst downgrades, are creating negative sentiment…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Smith+Nephew's ESSA Spatial Surgery System Receives FDA's De Novo Classification
Smith+Nephew (SNN) has secured FDA De Novo classification for its TESSA Spatial Surgery System, a significant regulatory milestone. This approval allows SNN to commercialize a new …
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 65
Standard Nuclear Shares Open For Trade At $13.50/Share; IPO Priced At $15/Share On 10M Shares
This headline signals a disappointing debut for Standard Nuclear, as its shares opened 10% below the IPO price. This immediate 'underpricing' suggests either overvaluation by the u…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 85
Standard Nuclear IPO Indicating $12/Share On 900K Shares; IPO Priced At $15/Share On 10M Shares
The significant increase in both the IPO price ($12 to $15) and the number of shares offered (900K to 10M) for Standard Nuclear suggests exceptionally strong investor demand, likel…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
Smith+Nephew shares are trading higher after the company announced the commercial launch of its LYNX COBLATION Laryngeal Wand, a multi-purpose solution for laryngology.
The commercial launch of the LYNX COBLATION Laryngeal Wand is a significant positive catalyst for Smith+Nephew. This new product expands their portfolio and addresses a specific ma…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.